Koomägi R, Volm M
Department of Oncological Diagnostics and Therapy, German Cancer Research Center, Heidelberg.
Int J Cancer. 1998 Feb 20;79(1):19-22. doi: 10.1002/(sici)1097-0215(19980220)79:1<19::aid-ijc4>3.0.co;2-z.
Tissue factor (TF) is the physiological initiator of blood coagulation. It has been suggested that TF also regulates tumor growth and angiogenesis. We therefore used immunohistochemistry to analyze the expression of TF and angiogenesis in non-small-cell lung carcinomas of 191 patients. A significant association was found between TF expression and microvessel density (MVD): TF-negative carcinomas more frequently exhibited low MVD. Additionally, a significant relationship between TF expression and the expression of vascular endothelial growth factor (VEGF) was discovered. TF was also compared with the resistance of the carcinomas to doxorubicin, as measured in vitro: TF-negative tumors were more frequently resistant to doxorubicin than were TF-positive tumors. Kaplan-Meier survival analysis revealed that survival times were longer in patients with TF-negative tumors than in patients with TF-positive tumors. These data suggest that TF functions as an additional angiogenic factor that could be used as a new prognostic and predictive factor for non-small-cell lung carcinomas.
组织因子(TF)是血液凝固的生理启动因子。有人提出TF也调节肿瘤生长和血管生成。因此,我们使用免疫组织化学分析了191例非小细胞肺癌患者中TF的表达和血管生成情况。发现TF表达与微血管密度(MVD)之间存在显著关联:TF阴性癌更常表现出低MVD。此外,还发现TF表达与血管内皮生长因子(VEGF)的表达之间存在显著关系。还将TF与体外测定的癌对阿霉素的耐药性进行了比较:TF阴性肿瘤比TF阳性肿瘤更常对阿霉素耐药。Kaplan-Meier生存分析显示,TF阴性肿瘤患者的生存时间比TF阳性肿瘤患者更长。这些数据表明,TF作为一种额外的血管生成因子,可作为非小细胞肺癌的新的预后和预测因子。